Please use this identifier to cite or link to this item:
Scopus Web of ScienceĀ® Altmetric
Type: Journal article
Title: Cyclooxygenase inhibitors: any reservations?
Author: Penglis, P.
James, M.
Cleland, L.
Citation: Internal Medicine Journal, 2001; 31(1):37-41
Publisher: Blackwell Science Asia
Issue Date: 2001
ISSN: 1444-0903
Abstract: The discovery of two cyclooxygenase isozymes, constitutive COX-1 and inducible COX-2, has resulted in the rapid development of selective inhibitors of COX-2, such as celecoxib and rofecoxib. Compared with traditional non-steroidal anti-inflammatory drug agents, use of COX-2 selective inhibitors is associated with decreased incidence of adverse gastric events as a result of minimal inhibition of gastroprotective COX-1, but with equivalent anti-inflammatory benefit through inhibition of COX-2. However, there is evidence to suggest that the 'COX-1 = constitutive, COX-2 = inflammatory' paradigm is less distinct than originally proposed. Futhermore, selective COX-2 inhibitors may have other consequences as a result of the change in the eicosanoid profile. Thus, despite the relatively safe gastrointestinal profile, vigilant post-marketing surveillance for other adverse effects is required.
Keywords: Animals
Tumor Necrosis Factor-alpha
Cyclooxygenase Inhibitors
Prostaglandin-Endoperoxide Synthases
DOI: 10.1046/j.1445-5994.2001.00002.x
Published version:
Appears in Collections:Aurora harvest
Medicine publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.